| Literature DB >> 31213810 |
Umar Farooq1, Touqeer Ahmad1, Ajmal Khan2, Rizwana Sarwar1, Jazib Shafiq3, Yasir Raza4, Ayaz Ahmed3, Safi Ullah5, Najeeb Ur Rehman2, Ahmed Al-Harrasi2.
Abstract
Background: Infections caused by drug resistant bacteria are a major health concern worldwide and have prompted scientists to carry out efforts to overcome this challenge. Researchers and pharmaceutical companies are trying to develop new kinds of antimicrobial agents by using different physical and chemical methods to overcome these problems. Materials and methods: In the present study, rifampicin conjugated silver (Rif-Ag) nanoparticles have successfully been synthesized using a chemical method. Characterization of the nanoparticles was performed using a UV-Vis spectrophotometer, FTIR, SEM, TEM, and AFM.Entities:
Keywords: AFM; Klebsiella pneumoniae; Staphylococcus aureus; TEM; antibiofilm; rifampicin; silver nanoparticles
Mesh:
Substances:
Year: 2019 PMID: 31213810 PMCID: PMC6549787 DOI: 10.2147/IJN.S198194
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Structure of rifampicin.
Figure 2Capping action of rifampicin with silver nanoparticles.
Figure 3Reaction optimization of rifampicin conjugated silver (Rif-Ag) nanoparticles.
Figure 4Heat effect on synthesis of nanoparticles.
Figure 5Stability of rifampicin conjugated silver (Rif-Ag) against brine solution.
Figure 6(A) pH effect on stability of rifampicin conjugated silver nanoparticles (Rif-Ag-NPs). (B) pH effect vs absorbance intensity.
Figure 7FTIR spectra of rifampicin and rifampicin conjugated silver (Rif-Ag) nanoparticles.
FTIR spectra assignment of free rifampicin and Rif-Ag nanoparticles
| Free Rifampicin | Rif-Ag Nanoparticles | Assignment |
|---|---|---|
| 3,483 cm−1 | — | |
| 2,972 cm−1 | 2,972 cm−1 | |
| 1,650 cm−1 | 1,650 cm−1 | |
| 1,797 cm−1 | 1,797 cm−1 | |
| 1,556 cm−1 | 1,556 cm−1 |
Abbreviations: FTIR, Fourier transform infrared spectroscopy; Rif-Ag, rifampicin conjugated silver.
Figure 8AFM images showing particles size distribution.
Figure 9(A) TEM images of rifampicin conjugated silver (Rif-Ag) nanoparticles. (B) Particle size of nanoparticles distribution.
Figure 10SEM images of rifampicin conjugated silver (Rif-Ag) nanoparticles.
Antimicrobial and biofilm inhibition activity of raifampicin and its synthesized nanoparticle
| Organisms | Rifampicin | Rifampicin nanoparticle | ||||
|---|---|---|---|---|---|---|
| MIC (μg/mL) | MBIC (μg/mL) | Biofilm % inhibition | MIC (μg/mL) | MBIC (μg/mL) | Biofilm % inhibition | |
| 2 | 2 | 41.78±5.1 | 8 | 4 | 37.29±2.5 | |
| 8 | 4 | 46.47±2.0 | 8 | 4 | 31.36±1.1 | |
| 4 | 2 | 66.45±8.2 | 4 | 1 | 94.65±1.1*** | |
| 4 | 4 | 44.6±3.3 | 4 | 4 | 28.6±2.0 | |
| 0.05 | 0.1 | 92.46±0.8 | 0.2 | 0.1 | 90.6±2.1 | |
| Methicillin Resistant | 0.012 | 0.003 | 64.94±2.5 | 0.025 | 0.003 | 93.53±0.2*** |
Notes: ***Statistically significant (P<0.05) as compared to free rifampicin.
Abbreviations: MBIC, minimum biofilm inhibitory concentration; MIC, minimum inhibitory concentration.
Preformed biofilm eradication capability of rifampicin and its synthesized nanoparticle
| Organisms | Rifampicin | Rifampicin nanoparticle | ||||
|---|---|---|---|---|---|---|
| Biofilm eradication dose (μg/mL) | Biofilm (%) eradication | Biofilm viability (%) reduction | Biofilm eradication dose (μg/mL) | Biofilm (%) eradication | Biofilm viability (%) reduction | |
| 10 | 26.3±3.8 | 20.37±1.2 | 1 | 40.25±0.9** | 52.12±1.7*** | |
| Methicillin Resistant | 1 | 52.69±6.2 | 33.62±0.5 | 1 | 69.21±1.4*** | 49.71±0.98** |
Note: **P<0.01, ***P<0.001.
Figure 11Biofilm eradicating potential of rifampicin and its nanoparticle.